Boothbay Fund Management’s Dyne Therapeutics DYN Stock Holding History

Boothbay Fund Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$680K	Buy	+30,600	New	+$569K	0.01%	1318
2025 Q4	–	Sell	-29,084	Closed	-$368K	–	2062
2025 Q3	$368K	Sell	29,084 -91,000	-76%	-$1.04M	0.01%	1332
2025 Q2	$1.14M	Buy	120,084 +5,006	+4%	+$55.1K	0.02%	644
2025 Q1	$1.2M	Buy	+115,078	New	+$1.65M	0.03%	576
2024 Q1	–	Sell	-57,200	Closed	-$761K	–	1659
2023 Q4	$761K	Buy	+57,200	New	+$559K	0.02%	813

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Boothbay Fund Management's DYN Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 30,600 shares worth $680K. The stake represents 0.01% of the portfolio and ranks #1318 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in DYN as recently as Q3 2025.

Boothbay Fund Management first reported a position in DYN in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.2M in Q1 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Boothbay Fund Management held 30,600 shares of Dyne Therapeutics worth $680K as of Q2 2026.
Dyne Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Dyne Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1318 holding.
Boothbay Fund Management first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 5 quarters since.
Boothbay Fund Management's Dyne Therapeutics position peaked at $1.2M in Q1 2025.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.